Last reviewed · How we verify
Erigeron breviscapus injection
Erigeron breviscapus injection reduces blood viscosity and improves microcirculation by inhibiting platelet aggregation and promoting vasodilation.
Erigeron breviscapus injection reduces blood viscosity and improves microcirculation by inhibiting platelet aggregation and promoting vasodilation. Used for Acute ischemic stroke, Cerebral infarction, Transient ischemic attack (TIA).
At a glance
| Generic name | Erigeron breviscapus injection |
|---|---|
| Sponsor | Guangzhou University of Traditional Chinese Medicine |
| Drug class | Traditional Chinese medicine extract; antiplatelet/microcirculation enhancer |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular; Cerebrovascular/Neurology |
| Phase | FDA-approved |
Mechanism of action
The extract from Erigeron breviscapus (a traditional Chinese medicinal plant) contains flavonoids and other active compounds that work to decrease blood viscosity, inhibit platelet aggregation, and improve blood flow in microvascular beds. These effects are thought to enhance tissue perfusion and reduce ischemic injury in cerebrovascular and cardiovascular conditions.
Approved indications
- Acute ischemic stroke
- Cerebral infarction
- Transient ischemic attack (TIA)
- Diabetic retinopathy
Common side effects
- Dizziness
- Headache
- Gastrointestinal discomfort
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: